AbbVie

AL.com reports Howard Jacob is leaving the HudsonAlpha Institute for Biotechnology after three years there.

Regeneron Pharmaceuticals and its collaborators plan to sequence the exomes all of the UK Biobank participants by then end of 2019.

By the end of 2019, Regeneron plans sequence the exomes of all 500,000 participants in the UK Biobank.

The project, dubbed FinnGen, was announced this week and is slated to run through mid-2023.

The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.

The team found that cancer-causing genes depend on the BTK gene, which they believe they can shut down with an existing drug.

The partners will use population genomics to discover and develop novel therapeutics and companion diagnostics for a range of chronic diseases.

Progression-free and overall survival seen in the veliparib arm weren't statistically significant, but were encouraging enough to move the drug to Phase III, AbbVie said.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.